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Abstract	
	
Infections	caused	by	bacteria	in	the	airway	preferentially	induce	a	Th17	response.		
However	the	mechanisms	involved	in	the	regulation	of	CD4	T	cells	responses	in	the	lungs	
are	incompletely	understood.		Here	we	have	investigated	the	mechanisms	involved	in	the	
regulation	of	Th17	differentiation	in	the	lungs	in	response	to	immunization	with	LPS	as	
adjuvant.		Our	data	shows	that	both	Myd88	and	TRIF	are	necessary	for	Th17	induction.		
This	distinctive	fate	determination	can	be	accounted	for	by	the	pattern	of	inflammatory	
cytokines	induced	by	airway	administration	of	LPS.		We	identified	the	production	of	IL-1b	
and	IL-6	by	small	macrophages	and	IL-23	by	alveolar	dendritic	cells,	favoring	Th17	
responses,	and	IL-10	repressing	IFN-g	production.		Furthermore,	we	show	that	exogenous	
IL-1β	can	drastically	alter	Th1	responses	driven	by	influenza	and	lymphocytic	
choriomeningitis	virus	infection	models	and	induce	IL-17	production.		Thus	the	precision	
of	the	lung	immune	responses	to	potential	threats	is	orchestrated	by	the	cytokine	
microenvironment,	can	be	repolarized	and	targeted	therapeutically	by	altering	the	
cytokine	milieu.		These	results	indicate	how	the	development	of	Th17	responses	in	the	lung	
are	regulated	by	the	cytokines	produced	by	lung	dendritic	cells	and	macrophages	in	
response	to	intranasal	immunization	with	LPS	adjuvant.	
	 	
Introduction	
	
The	lung	mucosa	is	a	major	site	of	interaction	of	the	immune	system	with	microbial	
pathogens	and	other	environmental	antigens	capable	of	stimulating	strong	responses	1,	2.		
In	view	of	the	necessity	to	maintain	lung	function	during	infection,	immune	responses	
tailored	to	maximize	elimination	of	pathogens	that	avoid	unnecessary	immune-mediated	
inflammation	and	cell	death	would	be	highly	desirable.		Here	we	explore	the	role	of	key	
adjuvants	in	determining	the	quality	of	CD4	T	cell	responses	and	provide	evidence	that	
such	responses	are,	indeed,	precisely	controlled	to	mount	responses	appropriate	to	
particular	microbial	threats.	
During	airway	immunization,	antigen-presenting	lung	DCs	migrate	to	the	
mediastinal	lung-draining	lymph	node	and	stimulate	antigen-specific	naïve	T	cells	3-5.		
Primed	CD4	T	cells	that	have	established	a	memory/effector	state	are	rapidly	mobilized	to	
the	airway	where	they	engage	the	pathogens	for	which	they	are	specific	6,	7.		Because	the	
lung	is	frequently	exposed	to	an	extensive	range	of	potentially	infectious	agents,	it	is	not	a	
surprise	that	it	contains	a	complex	network	of	DCs	and	macrophages	that	could	contribute	
to	the	induction	of	a	polarizing	microenvironment	appropriate	to	the	pathogen	as	revealed	
by	distinctive	patterns	of	CD4	T	cell	phenotypes	8,	9.		However,	it	is	not	clear	how	the	
interaction	of	mucosal	innate	and	CD4	T	cells	is	regulated	to	precisely	drive	the	
differentiation	of	responding	CD4	T	cells	to	distinctive	polarized	states	in	the	draining	node	
and	for	the	appropriate	migration	of	these	cells	to	the	lung	10.	
It	is	known	that	subcutaneous	immunizations	using	lipopolysaccharide	(LPS)	
adjuvant	or	intravenous	bacterial	infection	induce	a	broad	Th1	and	Th17	response,	while	
bacterial	intranasal	infection	can	predominantly	induce	a	Th17	response	11-13.		
Here,	using	a	T	cell	transfer	model,	we	have	investigated	the	mechanisms	driving	
the	differentiation	of	Th1	and	Th17	CD4	T	cells	in	the	airway	following	engagement	of	
single	TLRs.		Although	the	stimulation	of	most	toll-like	receptors	(TLR)	triggers	activation	
of	Myd88	signaling	pathway,	TLR4	-	which	recognizes	LPS	-	has	the	unique	characteristic	
among	TLRs	to	use	both	Myd88	and	TIR-domain-containing	adapter-inducing	interferon-β	
(TRIF)	while	TLR3	–which	recognizes	poly(I:C)	-	only	uses	TRIF	14.		Subsequently	we	have	
dissected	the	contribution	of	both	Myd88	and	TRIF	pathways	in	the	regulation	of	CD4	
helper	T	cell	polarization	in	response	to	airway	immunization.		We	have	analyzed	the	
control	of	Th17	effector	differentiation	by	cellular	and	cytokine	responses	to	intranasal	
immunization	using	LPS	as	adjuvant	in	parallel	with	poly(I:C)-dependent	Th1	
differentiation.		Furthermore,	the	analysis	of	the	pattern	of	inflammatory	cytokines	
produced	locally	in	response	to	airway	administration	of	LPS	or	poly(I:C)	and	the	
identification	of	their	cellular	origin	provide	insights	into	the	mechanisms	controlling	CD4	
Th17	cell	responses	induced	in	the	airway.	 	
Results	
	
CD4	T	cell	activation	in	response	to	intranasal	immunization	
To	analyze	the	regulation	of	CD4	helper	T	cell	differentiation	in	response	to	airway	
immunization,	we	have	used	a	well-established	adoptive	transfer	system:	105	to	106	TCR-
transgenic	CD4	T	cells	congenic	for	CD45.1	were	transferred	into	CD45.2	recipients.		The	
recipients	were	immunized	the	following	day	through	the	airway	with	antigen	plus	
adjuvant.	
Cells	were	isolated	from	the	lung-draining	mediastinal	lymph	node	(Med	LN),	the	
popliteal	lymph	node	(PLN)	and	the	lungs	at	various	times	and	stained	with	a	mixture	of	
antibodies	specific	for	CD4,	CD44,	CD45.1	and	CD45.2	to	identify	and	characterize	the	
transferred	TCR	transgenic	CD4	T	cells.		Initial	experiments	utilized	5C.C7	TCR	transgenic	
cells,	specific	for	a	pigeon	cytochrome	c	(PCC)	peptide.		In	a	recent	report	using	this	model,	
we	have	shown	that	within	2	hours	of	intranasal	immunization	with	LPS	+	PCC,	the	
frequency	of	5C.C7	cells	in	the	blood	diminished	dramatically,	followed	at	18	hours	by	
comparable	diminution	from	the	lung.		Numbers	of	5C.C7	cells	remained	constant	in	the	
Med	LN	over	this	period	(data	not	shown)	15.		Furthermore,	transferred	CD4	cells	quickly	
increased	expression	of	CD69	and	lost	CD62L	expression	in	the	Med	LN	following	
intranasal	immunization;	by	6h,	31%	of	the	cells	were	CD69+	and	by	12h,	97%	were	
CD69hi;	almost	¾	of	the	CD69hi	cells	were	also	CD62Llo	at	12h	(Fig.	S1a).		By	contrast,	at	
12h,	CD4	T	cells	resident	in	lung	or	lung	vasculature	maintained	a	naïve	phenotype	16-18.		By	
1.5	days	after	airway	immunization,	Med	LN	5C.C7	cells	had	completely	downregulated	
CD62L	and	Ly6C	(data	not	shown);	CD44	was	fully	upregulated.		71.8%	of	transferred	cells	
were	CD44hi	CD45RBlo	(Fig.	S1b).		5C.C7	cells	in	the	peripheral	lymph	nodes	were	only	
partially	activated	at	this	time.		24.3%	were	CD44hi	CD45RBlo,	only	reaching	full	activation	
on	day	5.		Thus,	the	initial	priming	occurs	mainly	in	the	Med	LN,	but	not	in	the	lungs.		As	
previously	shown	with	comparable	systems	with	bacterial	infection,	the	expansion	of	PCC-
specific	T	cells	reached	its	maximum	by	day	7	and	8;	their	frequency	diminished	rapidly	
until	day	10-12,	remaining	relatively	stable	or	diminishing	more	slowly	thereafter	(Fig.	
S1c)	6,	7.		5C.C7	cells	in	Med	LN,	PLN	and	lung	retained	an	activated/memory	phenotype	out	
to	60	days,	as	shown	in	Fig	S1b.	
		
Use	of	LPS	as	an	adjuvant	in	airway	immunization	leads	to	an	exclusive	IL-17-
producing	phenotype	
Airway	immunization	with	LPS	plus	PCC	resulted	in	Med	LN	and	lung	5C.C7	cells	
that	failed	to	produce	either	IFN-g	or	IL-4	6h	after	ex	vivo	stimulation.		31%	of	lung	and	
13%	of	Med	LN	5C.C7	cells	from	these	mice	produced	IL-17	(Fig.	1a-c)	13.		Labelling	5C.C7	T	
cells	with	CFSE	prior	transfer	revealed	that	IL-17-producing	cells	had	fully	diluted	their	
CFSE	(data	not	shown).		The	cytokine-producing	patterns	of	memory	phenotype	cells	were	
similar	to	those	of	the	“acutely”-primed	cells.		When	these	cells	were	analyzed	45	days	
later,	the	Med	LN	5C.C7	CD4	T	cells	still	retained	11.8%	IL-17	producing	capacity	(data	not	
shown).	
In	contrast	to	the	unique	IL-17-producing	phenotype	of	airway/LPS	primed	5C.C7	
cells,	single-dose	subcutaneous	immunization	utilizing	LPS	as	an	adjuvant	resulted	in	both	
IL-17	and	IFN-g-producing	PLN	cells	at	5	days.		22.1%	of	PLN	5C.C7	cells	produced	IFN-g	
while	26.7%	produced	IL-17	(Fig.	1d-e).		Such	“mixed”	LPS-induced	subcutaneous	priming	
was	also	observed	in	cells	in	the	Med	LN	of	these	mice,	where	18.6%	produced	IFN-g	and	
17.9%	produced	IL-17.		Similar	results	were	seen	in	other	studies:	intravenous	or	
intranasal	infection	with	Listeria	monocytogenes	induced	specific	CD4+	naïve	T	cells	to	
differentiate	into	Th1	or	Th17	respectively	6.		To	determine	where	the	priming	occurred,	
we	have	pre-treated	the	mice	with	FTY720	to	inhibit	DC	and	T	cell	migration	from	lymph	
nodes.		The	cells	from	subcutaneously	immunized	mice	in	the	PLN	still	produced	both	IFN-g	
and	IL-17	while	cells	in	the	Med	LN	exclusively	produced	IL-17,	implying	that	when	
priming	occurred	in	the	Med	LN	with	LPS	as	an	adjuvant,	the	response	was	limited	to	the	
production	of	IL-17.		This	suggests	that	it	is	the	locus	of	priming,	not	the	site	of	introduction	
of	antigen,	that	determines	the	outcome	of	LPS	adjuvanted	priming	6,	19,	20.		This	argument	
was	further	strengthened	by	transferring	in	vitro-primed	Th1	or	Th17	CD4	T	cells	into	
normal	mice	that	were	then	challenged	either	intranasally	or	subcutaneously	with	antigen	
plus	LPS,	the	transferred	cells	retained	their	initial	cytokine-producing	phenotype	(data	not	
shown).		Thus,	the	local	microenvironment	is	most	important	during	the	priming	phase	of	
the	immune	response.	
	
	
Poly(I:C)	adjuvant	favors	Th1	differentiation	in	Mediastinal	LN	
To	further	investigate	the	contribution	of	LPS	to	the	response	restricted	to	Th17,	we	
have	compared	LPS	with	another	adjuvant:	poly(I:C).		While	responsiveness	to	LPS,	the	
major	structural	component	of	the	outer	wall	of	Gram-negative	bacteria,	is	mediated	by	
Toll-like	receptor	4	(TLR4),	responsiveness	to	poly(I:C),	an	analog	of	double-stranded	RNA,	
is	mediated	by	TLR3.		TLR	4	uses	both	a	Myd88-	and	a	TRIF/TRAM-signaling	pathway	
while	TLR3	signaling	is	confined	to	the	TRIF	pathway,	although	TRAM	is	not	involved	21.		In	
contrast	to	LPS	adjuvant	action	in	the	airway,	intranasal	immunization	with	poly(I:C)	
induced	PCC-specific	CD4	T	cells	to	secrete	only	IFN-γ	(Fig.	2a-b).		6	days	after	
immunization,	5C.C7	CD4	T	cells	found	in	the	lungs	and	the	draining	lymph	nodes	from	
mice	immunized	with	LPS	plus	PCC	secreted	IL-17	upon	stimulation	(28.2%	in	the	lungs;	
12.2%	IL-17	in	Med	LN)	while	those	immunized	with	PCC	plus	poly(I:C)	exclusively	
produced	IFN-g	(19.5%	in	the	lungs	and	12.1%	in	Med	LN).	
	
	
MyD88	and	TRIF	control	the	polarized	secretion	of	cytokines	
We	asked	whether	the	distinctive	pattern	of	CD4	T	cell	polarization	was	dependent	
upon	differences	in	the	signalling	pathways	activated	by	these	adjuvants	14.		Because	most	
TLR-associated	molecule	knockouts	are	available	on	a	C57BL/6	background,	we	used	OT-II	
TCR	transgenic	CD4	T	cells	transferred	into	wild-type	and	various	gene-deleted	C57BL/6	
recipients	and	assessed	the	types	of	responses	induced	by	airway	immunization	with	
ovalbumin	(OVA).		Our	initial	hypothesis	was	that	Myd88	would	be	driving	the	Th17	
differentiation	in	response	to	LPS	and	TRIF	would	not	be	used.		Not	surprisingly,	recipients	
that	lacked	TLR3	or	the	type	I	interferon	receptor	(TLR3-/-	or	IFNAR-/-		recipients)	failed	to	
support	differentiation	of	OT-II	cells	to	the	production	of	IFN-g	nor	did	these	cells	acquire	
IL-17-producing	capacity	(Fig.	3a,	b).		As	previously	reported,	this	indicates	that	poly(I:C)	
mediates	its	effects	through	type	I	interferon	production,	as	a	result	of	TLR3-mediated	
signaling	22,	23.		
Since	LPS	can	use	both	the	MyD88	and	TRIF	pathways,	we	tested	the	capacity	of	
recipients	deficient	in	one	or	the	other	for	their	response	to	airway	immunization	with	OVA	
plus	LPS.		To	test	the	TRIF	pathway,	we	used	TRAM-/-	recipients;	TRAM	is	the	adaptor	
molecule	that	links	TLR4	to	TRIF	24.		As	shown	in	Fig.	3c,	d,	in	TRAM-/-	recipients,	intranasal	
immunization	with	LPS	plus	OVA	led	to	neither	IL-17	nor	IFN-g	production	by	the	OT-II	
cells,	suggesting	that	TRIF	is	critical	to	Th17	differentiation.		Similarly,	low	levels	of	LPS	
present	in	inhaled	allergens	have	been	reported	to	induce	IL-17	production	using	the	TRIF	
pathway	13.	
MyD88-/-	recipients	immunized	with	OVA	and	LPS	lost	the	capacity	to	make	an	IL-17	
response	in	both	Med	LN	and	lungs.		In	its	place,	OT-II	cells	in	these	mice	developed	a	
robust	IFN-g	response.		This	strongly	suggests	that	the	MyD88-signalling	pathway	is	
necessary	for	the	production	of	IL-17	and	that	it	directly	or	indirectly	represses	the	
induction	of	an	IFN-γ	response.		
Deletion	of	TRAM	or	MyD88	had	no	effect	on	the	capacity	of	poly(I:C)	to	induce	an	
IFN-g	response	(Fig.	S2).		This	is	not	surprising	since	TLR3	links	directly	to	TRIF	without	
the	need	from	TRAM	as	an	intermediate.		
	
	
Cytokine-Production	in	Response	to	Airway	Instilled	Adjuvants	
To	understand	how	Myd88	and	TRIF	signalling	pathways	in	the	host	regulate	
acquisition	of	cytokine-producing	phenotype	by	wild-type	CD4	T	cells,	we	analyzed	
production	of	key	cytokines	in	the	lungs	in	response	to	airway	introduction	of	either	LPS	or	
poly(I:C).		12	to	18h	after	intranasal	introduction	of	LPS	or	poly(I:C),	we	analyzed	cytokine	
content	in	the	broncho-alveolar	(BAL)	fluid.		We	found	that	LPS	induced	IL-6,	IL-10	and	IL-
1b	but	little	if	any	IFN-γ	and	modest	amounts	of	IL-12p70	(Fig.	3e).		By	contrast,	poly(I:C)	
strikingly	induced	IFN-γ	and	IL-12	p70	but	little	or	no	IL-6,	IL-10	or	IL-1b.			
IL-1β,	IL-6	and	IL-23	are	known	to	play	important	roles	in	Th17	differentiation	so	
that	the	capacity	of	LPS	to	induce	IL-17-producing	CD4	T	cells	and	the	failure	of	poly(I:C)	to	
do	so	is	reasonable.		TGF-b	production	by	dendritic	cells	in	response	to	bacterial	intranasal	
infection	has	been	shown	to	participate	in	Th17	differentiation	in	the	airway	12.		Further,	
production	of	type	I	interferon	and	IL-12	in	response	to	poly(I:C)	but	not	LPS	is	consistent	
with	the	latter	but	not	the	former	inducing	a	Th1	response	(Fig.	3e,	S3).			
The	TRAM-/-	mouse	produces	~10-fold	less	IL-1b	in	response	to	LPS	than	does	the	
wild-type	animal,	consistent	with	its	limited	capacity	to	support	a	Th17	response,	although	
its	production	of	IL-6	remains	normal	(Fig.	3e).		The	MyD88-/-	mouse	failed	to	produce	
either	IL-6	or	IL-1b in	response	to	LPS,	consistent	with	its	inability	to	mount	a	Th17	
response	in	response	to	LPS.		It	also	failed	to	produce	IL-10	but	did	produce	ample	IL-12,	
consistent	with	the	production	of	IFN-g	rather	than	IL-17	by	OT-II	cells	transferred	to	this	
animal.			
To	further	characterize	the	cellular	origin	of	these	helper	T	cell-inducing	cytokines,	
we	analyzed	lung	cytokine	production	by	intracellular	staining	of	mice	treated	intranasally	
with	LPS	or	poly(I:C)	and	the	lungs	were	harvested	48h	later.		IL-1β	pro-form	and	IL-6	
induced	by	LPS	were	mainly	produced	by	CD11c-	CD11b+	F4/80+	small	macrophages,	
while	IL-23p19	was	produced	by	CD11c+	CD11b+	alveolar	dendritic	cells	(Fig.	S3a,	b).		
Similarly,	IL-6	induced	by	poly(I:C)	was	also	found	in	small	macrophages.		By	contrast,	Th1-
polarizing	cytokines	IFNa 	and	IL-12p35	induced	by	poly(I:C)	were	produced	by	CD11c+	
CD11b-	alveolar	macrophages,	also	expressing	Siglec-F	under	inflammatory	conditions.			
	
	
Th1	differentiation	in	the	airway	is	controlled	by	relative	amounts	of	IL-10	and	IL-12	
To	assess	the	significance	of	the	altered	cytokine	environments	in	normal	and	gene	
knockout	mice	treated	with	either	LPS	or	poly(I:C),	we	treated	recipients	of	5C.C7	cells	
with	either	exogenous	cytokines	or	neutralizing	anti-cytokine	antibodies	at	the	time	of	
immunization.		Intranasal	treatment	with	exogenous	IL-10	completely	inhibited	induction	
of	IFN-γ-producing	cells	in	response	to	airway	immunization	with	PCC	and	poly(I:C)	while	
induction	of	IL-17-producing	cells	in	response	to	LPS	immunization	was	unaffected	(Fig.	
4a,	b).	Anti-IL-10	treatment	of	mice	immunized	with	PCC	plus	LPS	resulted	in	the	
appearance	of	IFN-g-	and	IL-17-	single	producing	CD4	T	cells	(Fig	4c,	d).		That	is,	with	only	
modest	inhibition	of	Th17	differentiation,	neutralization	of	IL-10	allowed	a	Th1	response	to	
occur,	mimicking	what	is	seen	in	subcutaneous	immunization	with	antigen	plus	LPS	(Fig.	
1d).		Similarly,	a	previous	report	showed	that	the	rapid	release	of	IL-10	following	LPS	
intraperitoneal	injection	suppresses	LPS-induced	IFN-γ	release,	while	neutralization	
results	in	increased	IFN-γ	levels	25.			
IL-12	treatment	of	mice	immunized	with	PCC	plus	LPS	led	the	responding	T	cells	to	
develop	an	almost	exclusive	Th1	response	(Fig.	4e,	f),	implying	that	the	presence	of	large	
amounts	of	IL-12	could	both	induce	a	Th1	response	and	suppress	a	Th17	response.		
Consistent	with	this	idea,	anti-IL-12	treatment	of	mice	immunized	with	PCC	plus	poly(I:C)	
resulted	in	diminished	IFN-g	production	by	the	responding	T	cells	as	well	as	the	
appearance	of		T	cells	capable	of	producing	IL-17	(Fig.	4e,	f).		
	
	
Control	of	Th17	Differentiation	by	IL-1b		
We	previously	described	a	direct	effect	of	IL-1b	on	in	vivo	CD4	and	CD8	T	cells	
during	primary	and	secondary	responses	to	subcutaneous	immunization	26,	27.		IL-1b	
dramatically	enhanced	both	T	cell	expansion	and	the	proportion	of	CD4	T	cells	producing	
IL-17.		Considering	the	established	role	of	IL-1b	in	increasing	the	frequency	of	Th17	cells	
during	in	vitro	priming	28,	we	have	investigated	the	importance	of	IL-1b	in	our	system	of	
airway	immunization.		The	addition	of	IL-1b	to	airway	priming	with	PCC	plus	LPS	increased	
the	frequency	of	5C.C7	cells	by	almost	ten-fold	(Fig.	5a).		The	addition	of	IL-1b	also	caused	
~5-fold	increase	in	the	frequency	of	IL-17-producing	5C.C7	cells	in	mice	when	compared	to	
mice	that	received	the	IL-1	receptor	antagonist	(IL-1Ra;	Anakinra)	(Fig.	5b,	c).		Taking	the	
increase	in	the	absolute	number	of	5C.C7	cells	together	with	the	increase	in	the	frequency	
of	IL-17-producing	5C.C7	cells,	IL-1b	treatment	results	in	an	~25-fold	increase	in	the	
absolute	number	of	IL-17-producing	cells	in	response	to	airway	immunization.		This	IL-1b-
mediated	effect	enhances	both	IL-17A	and	F	production	(data	not	shown)	and	is	on	the	T	
cells	themselves	since	it	is	observed	when	wild-type	OT-II	cells	are	transferred	to	IL-1R1-/-	
recipients	(Fig.	S4).	
The	addition	of	exogenous	IL-1b	to	airway	immunization	with	PCC	plus	poly(I:C)	
was	sufficient	to	induce	the	secretion	of	IL-17	(Fig.	5d,	e)	while	modestly	diminishing	the	
production	of	IFN-g	in	response	to	such	immunization,	suggesting	that	the	absence	of	IL-1β	
prevents	the	generation	of	IL-17	or	that	IL-1β	addition	overcomes	the	need	for	another	
pathway.	
	
	
Cytokine	environment	determines	the	type	of	response	
As	shown	in	Fig.	3e,	LPS	administration	to	wild-type	mice	results	in	production	of	
IL-1b	and	IL-10	in	the	BAL.		By	contrast,	airway	administration	of	LPS	to	Myd88-/-	mice	fails	
to	induce	either	cytokine.		The	altered	pattern	of	IL-17	and	IFN-g	production	by	OT-II	cells	
primed	in	Myd88-/-	recipients	might	be	explained	by	the	differences	in	IL-10,	IL-12	and	IL-
1b	production	in	these	mice	29.			
To	test	this	hypothesis,	we	have	transferred	OT-II	cells	to	Myd88-/-	recipients	that	
were	immunized	with	OVA	plus	LPS	made	an	IFN-g	response	in	the	Lung.		Administration	
of	IL-10	inhibited	this	response	but	did	not	“rescue”	the	IL-17	response,	arguing	that	IL-10	
inhibited	the	IFN-g	response	but	was	not	important	for	the	induction	of	IL-17	(Fig.	6a,	c).		
By	contrast,	administration	of	IL-1b	to	Myd88-/-	mice	recipients	of	OT-II	cells	primed	with	
OVA	plus	LPS,	while	not	diminishing	the	IFN-g-response,	resulted	in	a	robust	IL-17	
response.		
Administration	of	IL-1b	to	a	TRAM-/-	recipient	also	allowed	the	transferred	OT-II	
cells	to	produce	IL-17	in	response	to	OVA	plus	LPS,	implying	that	it	is	the	deficiency	of	IL-
1b	in	both	Myd88-/-	and	TRAM-/-	mice	that	prevents	a	Th17	response	in	such	recipients	of	
OT-II	cells	and	thus	implying	that	both	the	Myd88	and	TRIF	pathways	are	needed	for	an	
LPS-induced	IL-1b	production	(Fig.	6b,	c).		Finally,	the	failure	of	TRAM-/-	recipients	of	OT-II	
cells	to	make	an	IFN-g	response	can	be	overcome	by	administration	of	IL-12.		This	is	
consistent	with	failure	of	IL-12	production	in	both	the	wild-type	and	TRAM-/-	mice,	
presumably	accounted	for	by	the	robust	production	of	IL-10	in	both	animals.		
Thus,	inhibition	of	IFN-g-production	in	wild-type	mice	immunized	through	the	
airway	with	antigen	plus	LPS	can	be	attributed	to	Myd88-dependent	IL-10	production	and	
the	failure	of	IL-12	production,	presumably	as	a	consequence,	while	the	production	of	IL-17	
by	T	cells	in	such	animals	can	be	attributed	to	Myd88-	and	TRAM-dependent	IL-1b	
production.			
	
	
IL-1b	induces	a	Th17	response	in	the	course	of	an	influenza	infection	
Based	on	all	the	results,	we	theorize	that	fine-tuning	the	cytokine	microenvironment	
in	the	lungs	can	dramatically	alter	the	choice	of	helper	T	cell	differentiation.		Using	a	live	
infection	that	induces	a	Th1	response	in	the	airway,	we	have	assessed	whether	providing	
IL-1b	during	an	infection	that	strongly	induces	a	CD4	IFN-g	response	would	also	polarize	to	
a	Th17	response.		We	studied	priming	of	CD4	T	cells	in	mice	that	were	infected	intranasally	
with	the	non-lethal	influenza	strain	H1N1	virus	Tx91	30,	31.		As	shown	in	Fig.	7a,b,	
endogenous	lung	CD4	T	cells	made	a	response	to	influenza	dominated	by	the	capacity	of	
CD4	T	cells	to	produce	IFN-γ.		The	addition	of	IL-1b	increased	the	proportion	of	IL-17	
producers	in	the	lung	but	did	not	affect	IFN-γ-producing	cells;	only	a	modest	proportion	of	
the	IFN-g-producers	also	produced	IL-17.		No	increase	in	IL-17	producers	was	observed	in	
the	Med	LN.		During	rheumatoid	arthritis,	IL-23p19	and	IL-6	expression	can	be	induced	by	
IL-1β	via	NF-kB,	suggesting	that	the	addition	of	IL-1β	during	influenza	can	induce	IL-23p19	
and	IL-6	in	a	similar	fashion	32,	33.			
In	addition,	we	analyzed	the	lung	immunopathological	consequences	of	providing	
IL-1β	during	influenza	infection:	immunohistochemistry	analysis	of	lung	sections	shows	
excessive	peri	alveolar	and	transmural	inflammatory	cell	infiltrates,	and	goblet	cells	
metaplasia	when	IL-1β	is	added	during	Tx91	infection	(Fig.	7,	S5).		Similar	excessive	
immunopathology	is	observed	in	mice	infected	with	influenza	and	treated	with	E.	coli	LT-
IIb	34.		An	even	more	striking	IL-1b-mediated	induction	of	endogenous	CD4	T	cells	to	adopt	
a	Th17	phenotype	occurred	in	mice	infected	with	lymphocytic	choriomeningitis	virus	(Fig.	
S6),	with	the	frequency	of	IL-17-producers	in	the	lung	increasing	from	10%	to	37%.			
	
	 	
Discussion	
Our	results	suggest	that	in	response	to	intranasal	immunization	using	LPS	as	
adjuvant:	Myd88-dependent	IL-1β	production	by	lung	macrophages	and	the	expression	of	
TRIF	are	required	for	Th17	differentiation,	and	that	Myd88-dependent	IL-10	production	is	
required	for	Th1	inhibition.		Although	our	data	support	recent	reports	that	intranasal	
infection	by	bacteria	induces	a	Th17	response	6,	12,	its	molecular	regulation	at	the	cellular	
and	cytokine	levels	remain	unclear.		Here,	we	have	explored	the	regulation	of	Th17	airway	
responses	and	have	shown	that	the	distinctive	pattern	of	inflammatory	cytokines	produced	
in	response	to	the	two	adjuvants	LPS	and	poly(I:C),	can	account	for	the	highly	polarized	
CD4	T	cell	responses	elicited.		We	have	systematically	analyzed	the	regulation	of	Th17	
differentiation,	as	a	consequence	of	the	Myd88/	TRIF	signalling	cascade	in	response	to	TLR	
ligands	and	subsequent	regulation	and	cellular	origin	of	the	polarizing	cytokines	in	the	
airway.		New	findings	in	this	study	provide	a	better	understanding	of	the	interconnection	
between	adjuvants	and	polarizing	cytokines	during	Th17	differentiation	in	the	airway.	
Subcutaneous	immunization	utilizing	LPS	as	an	adjuvant	generally	results	in	a	CD4	
T	cell	mixed	response	in	the	sense	that	cells	capable	of	secreting	IFN-g,	IL-4	or	IL-17	are	
induced	to	varying	degrees	26,	35,	36,	37.		We	and	others	have	observed	that	the	response	to	
LPS	or	bacterial	airway	immunization	is	largely	limited	to	cells	that	produced	IL-17	upon	in	
vitro	challenge	6.		Nonetheless	the	distinctive	Th17-only	cytokine	profile	with	intranasal	
immunization	compared	with	the	mixed	response	induced	by	a	systemic	immunization	has	
not	been	explained.		One	can	argue	that	great	precision	should	be	required	of	a	response	
aimed	at	lung	infections	since	in	the	lung,	among	all	mucosal	tissues,	an	inappropriate	
effector	response	is	apt	to	be	of	the	greatest	consequence.		For	example,	inappropriate	
mobilization	of	neutrophils	in	the	case	of	a	virus	infection	might	lead	to	a	marked	reduction	
in	airway	function,	at	great	cost	to	the	individual,	with	little	or	no	apparent	immune	benefit	
38,	39.	
In	the	present	study,	the	analysis	of	cytokines	in	the	broncho-alveolar	lavage	fluid	
18	hours	after	airway	introduction	of	LPS	showed	substantial	amounts	of	IL-6,	IL-1b and	
IL-10	and	little	to	no	IL-12.		IL-1b	pro-form	and	IL-6	were	both	detected	in	lung	small	
macrophages	while	IL-23	was	made	by	lung	alveolar	DC.		A	recent	report	showed	that	IL-6	
and	TGF-b	production	by	dendritic	cells	is	required	for	Th17	differentiation	in	the	lungs.	
Our	data	show	that	neutralization	of	IL-1b	markedly	reduced	the	frequency	of	LPS-induced	
IL-17-producing	cells	without	enhancing	an	IFN-g	response,	in	keeping	with	the	known	
effects	of	IL-1b	in	the	development	of	Th17	cells	28.		Furthermore,	we	found	that	exogenous	
intranasal	IL-1β	can	induce	Th17	effector	cells	independently	of	the	Th1	response	induced	
by	poly(I:C).		We	also	show	that	neutralizing	IL-10,	while	only	moderately	diminishing	the	
Th17	response	to	LPS,	resulted	in	the	appearance	of	IFN-g-producing	cells.		This	was	
associated	with	the	appearance	of	IL-12	in	the	BAL,	implying	that	IL-10	produced	in	
response	to	LPS	blocked	the	production	of	IL-12	and	thus	blocked	the	induction	of	a	Th1	
response.		Indeed,	administration	of	excess	IL-12	in	the	airway	of	mice	immunized	with	
LPS	adjuvant	fully	polarized	the	response	to	the	Th1	phenotype.	
The	distinctive	pattern	of	cytokines	induced	upon	LPS	treatment	was	shown	to	
depend	upon	the	signalling	pathways	activated	by	TLR4	40.		A	recent	study	showed	that	
TRIF	expression	by	lung	dendritic	cells	induces	a	Th17	response	associated	with	
neutrophilic	asthma13.		Our	LPS	intranasal	immunization	model	supports	this	and	shows	
that	when	TRAM-/-	mice	-	in	which	the	TLR4	TRIF	pathway	is	disabled	but	the	Myd88	
pathway	remains	intact	-	were	immunized,	IL-1b	production	was	blocked	but	IL-10	
continued	to	be	made,	accounting	for	the	lack	of	a	Th17	and	a	Th1	response	respectively	41.		
Additionally,	deletion	of	Myd88	had	an	even	more	dramatic	effect	since	in	its	absence	LPS	
failed	to	induce	IL-1b,	IL-10	and	IL-12.		Thus,	the	Th17	response	to	intranasal	
immunization	with	LPS	required	the	expression	of	either	TRIF	or	Myd88	and	failed	to	occur	
presumably	because	of	the	absence	of	IL-1b.		In	its	place,	while	IL-12	levels	remained	very	
low,	in	the	absence	of	IL-10	a	robust	Th1	response	occurred.		This	implies	that	in	the	
airway,	IL-1b	production	in	response	to	LPS	requires	contributions	from	signalling	through	
both	the	TRIF	and	Myd88	pathways	and	only	if	both	pathways	are	intact	does	LPS	act	to	
promote	a	Th17	response	by	transferred	OT-II	cells.		Indeed,	it	has	been	reported	that	in	
response	to	TLR4-dependent	LPS	signalling	in	DCs	and	macrophages,	Myd88	is	important	
in	pro-IL-1b	production	while	TRIF	is	needed	for	IL-1b	maturation	42,	43.		Furthermore,	we	
show	that	in	the	absence	of	IL-10,	LPS	intranasal	immunization	can	induce	IFN-γ,	
suggesting	that	just	like	in	a	subcutaneous	immunization,	LPS	has	the	potency	to	induce	
IFN-γ,	but	that	this	pathway	is	inhibited	by	the	production	of	IL-10	in	the	airway.	
The	capacity	of	poly(I:C)	to	enhance	a	Th1	response	can	also	be	traced	to	the	pattern	
of	inflammatory	cytokines	induced	in	BAL.		Thus,	our	data	show	that	poly(I:C)	induces	IFN-
γ	and	IL-12	in	BAL,	and	IFNa	and	IL-12	production	by	alveolar	macrophages	22,	44.		Also	
while	blocking	IL-12	in	our	model	diminishes	the	Th1	response	induced	by	poly(I:C),	
treating	mice	with	IL-10	both	blocks	IL-12	production	and	prevents	the	Th1	differentiation	
45,	46.		Interestingly	two	different	cell	types	are	mainly	involved:		whilst	we	show	that	
alveolar	macrophages	are	the	major	cell	type	producing	Th1-polarizing	cytokines,	small	
macrophages	are	restricted	to	make	Th17-inducing	cytokines.	
Although	our	analysis	is	based	on	an	adoptive	transfer	model,	it	is	consistent	with	
our	observations	in	two	infectious	systems.		We	used	influenza	or	LCMV	infections	that	
induce	highly	polarized	Th1	responses	in	the	lung,	consistent	with	the	importance	of	IFN-g	
in	controlling	these	infections	30,	47.		Our	data	shows	that	instilling	IL-1b	in	the	airway	in	
both	settings	strikingly	induces	a	lung	Th17	response	arguing	that	such	responses	in	the	
lung	fine-tune	CD4	T	cell	differentiation	and	that	IL-1b	remains	the	key	to	Th17	production	
in	infectious	settings	just	as	it	does	in	model	systems.		A	previous	report	has	shown	
significant	increased	mortality	with	IL-1R-/-	mice	during	lethal	H1N1	influenza	infection,	
and	suggested	that	although	IL-1a/b	may	increase	pulmonary	inflammatory	pathology,	it	
enhances	survival	48.		Although	the	strain	we	used	was	not	lethal,	our	data	suggest	that	the	
IL-1β-induced	Th17	response	could	be	in	part	responsible	for	the	increased	survival	and	
the	acute	pneumonia.		Keeping	in	mind	that	neutrophilia	is	elevated	in	the	majority	of	cases	
of	COPD	in	patients;	the	excessive	recruitment	of	neutrophils	could	largely	outweight	the	
benefit	of	the	Th17	response.		Furthermore,	our	results	with	mice	infected	with	influenza	
and	treated	with	IL-1β	support	another	study	where	induction	of	IL-17	and	IL-22,	and	
increased	bacterial	clearance	were	seen	in	mice	co-infected	with	influenza	A	H1N1	and	
Staphylococcus	aureus	when	IL-23	is	overexpressed	49.		As	combined	influenza	and	
bacterial	pneumonia	are	among	the	most	deadly	infectious	diseases,	it	is	critical	to	
understand	the	mechanisms	of	increased	susceptibility	to	superinfection	in	the	lung	and	
subsequent	coordinated	cellular	and	cytokine	responses	to	effectively	control	the	infection.			
Our	results	further	suggest	that	airway	vaccinations	for	resistance	to	lung	
pathogens	need	to	use	or	select	adjuvants	to	tailor	the	immune	response	and	generate	
efficient	protective	immunity.		We	argue	that	CD4	T	cell	responses	in	the	lung,	perhaps	
more	than	in	any	other	tissue,	need	to	be	regulated	with	exquisite	precision	if	they	are	not	
to	avoid	to	severe	immunopathology	perhaps	coupled	with	poor	protection.		Ultimately,	
therapeutic	targeting	of	key	polarizing	cytokines	during	the	early	steps	of	the	immune	
response	can	reprogram	the	cytokine	microenvironment	in	the	airway	and	allow	control	of	
the	inflammatory	response.	 	
Materials	and	Methods	
	
Mice	
B10.A	and	B10.A.SJL-Rag2-/-	-Ptprca-5C.C7(TcRa,	TcRb)	were	obtained	from		Taconic	Farms	
(Germantown,	NY).	C57BL/6,	C57BL/6	OT-II	(B6.Cg-	Tg	(TcraTcrb)	425Cbn/J,	Tram-/-		
C57BL/6J-	Ticam1Lps2/J,	TLR3-/-		B6;129S1-	Tlr3tm1Flv/J,	MyD88-/-		CBy.129P2(B6)	-
MyD88tm1Defr/J,	IFNAR-/-		B6.129S2-	Ifnar1tm1Agt/Mmjax,	IL-1R-/-		B6.129S7-	
Il1r1tm1Imx/J	were	purchased	from	Jackson	Laboratories	(Bar	Harbor,	ME).		All	mice	were	
housed	under	specific	pathogen-free	animal	conditions	at	the	National	institute	of	Allergy	
and	Infectious	Diseases	(NIAID),	and	used	between	6	and	12	weeks	of	age	in	accordance	
with	guidelines	provided	by	the	Institutional	Animal	Care	and	Use	Committee	of	the	NIAID.	
	
Viruses	
Mice	were	infected	with	106	pfu	Influenza	H1N1	virus	A/Texas/36/91	(provided	by	
Marlène	Brandes,	LSB,	NIAID).		Mice	infected	with	LCMV	were	inoculated	intraperitoneally	
with	2	x	105	pfu	Clone	13	(provided	by	George	A.	Punkosdy,	LI,	NIAID).	
	
Isolation	of	Lung	cells	
Mice	were	bled	by	intracardiac	puncture	and	lungs	were	extensively	perfused	with	HBSS	
before	being	harvested.		Lungs	were	minced	with	gentleMACS	dissociator	(Miltenyi	Biotec)	
and	digested	in	Liberase	TM	with	DNase	I	(Invitrogen)	for	30	minutes	at	37˚C.		The	reaction	
was	stopped	by	adding	EDTA.		The	digested	tissue	was	processed	on	a	40µm	cell	strainer	
(BD	Biosciences),	and	a	single	cell	suspension	was	enriched	on	a	40/60%	Percoll	gradient	
centrifugation	(GE	Healthcare).		
	
Adoptive	Cell	Transfer	
CD4	T	cells	from	5C.C7	or	OT-II-Tg	mice	were	isolated	from	lymph	nodes.		105-106	cells	
were	adoptively	transferred	by	intravenous	injection	into	the	retro-orbital	sinus	of	each	
recipient.		When	specified,	cells	were	labeled	with	1µM	carboxyfluorescein	succinimidyl	
ester	(Sigma)	for	5min	at	37˚C	prior	transfer.		After	transfer,	cells	were	allowed	to	home	for	
24h.	
	Immunization	and	in	vivo	treatments	
Mice	were	immunized	intranasally	or	subcutaneously	in	the	hock	with	antigen	plus	
adjuvant.		100µg	ovalbumin	or	pigeon	cytochrome	c	(Sigma)	were	used	with	either	2.5µg	
lipopolysaccharide	(Sigma)	or	20µg	polyinosinic:polycytidylic	acid	(Invivogen).		For	
cytokine	instillation,	mice	were	given	1µg	of	recombinant	IL-1b,	IL-6,	IL-10,	IL-12	
(Peprotech)	or	100µg	IL-1Ra	(Kineret)	12	to	18h	after	OVA	or	PCC	challenge.		Where	
indicated,	250µg	of	anti-mouse	IL-6	(MP5-20F3),	anti-mouse	IL-10	(JES5-2A5)	(BioXCell)	
or	anti-mouse	IL-12	were	injected	intraperitoneally	12h	before	antigen	challenge.	In	some	
experiments,	mice	were	injected	intraperitoneally	with	40µg	FTY720	(Calbiochem)	12-18h	
after	antigen	challenge.	
	
Analysis	of	airway	cytokines	
Whole	lung	lavage	was	performed	in	mice	treated	with	LPS	or	poly(I:C)	overnight.		The	
trachea	was	intubated	with	an	oral	needle,	800µl	medium	was	infused	and	the	volume	was	
retrieved.		Concentrations	of	IL-1b,	IL-6,	IL10,	IL-12p70	and	IFN-γ	were	assessed	by	
multiplex	Cytometric	Bead	Array	and	analyzed	with	FCAP	Array	software	according	to	the	
manufacturer’s	instructions	(BD	Biosciences).		IL-6	analysis	is	shown	with	broncho-
alveolar	lavages	diluted	at	1:10.	
For	intracellular	staining,	lungs	were	harvested	at	48h,	kept	in	vitro	for	6h	with	monensin	
before	staining.	
	
Flow	Cytometry	
Lymph	nodes	and	lungs	were	harvested	and	single-cell	suspensions	were	prepared	in	HBSS	
plus	FCS,	sodium	azide	and	EDTA.		For	intracellular	cytokine	staining,	cells	were	stimulated	
with	10ng/ml	phorbol	12-myristate	13-acetate	and	1µM	ionomycin	in	presence	of	2µM	
Monensin	for	6h,	before	being	fixed,	permeabilized	and	then	stained.		Antibodies	to	Ly6C	
(AL21),	CD62L	(MEL14),	CD45RB	(16A),	CD69	(H1.2F3),	CD4	(RM4),	CD45.1	(A20),	CD45.2	
(104),	IL-2	(JES6-5H4),	IL-4	(11B11),	IL-13,	IL-17A	(TC11-18H10),	IL-17F	(O79-289)	were	
purchased	from	BD	Biosciences.		IL-1β	pro-form	(NJTEN3),	IL-23	p19	(fc23cpg)	were	from	
eBioscience;	CD8	(53-6.7),	CD11c	(N418),	IL-6	(MP5-20F3)	were	from	BioLegend	and	IL-12	
p35	(27537)	from	R&D	systems.		Siglec	F	(E50-2440),	CD11b	(M1/70)	and	F4/80	(BM8)	
were	a	gift	from	Awen	Gallimore	(I&I,	Cardiff,	UK).		After	staining,	cells	were	visualized	
through	LSRII	or	LSR	Fortessa	flow	cytometer	(BD	Biosciences)	and	analyzed	with	FlowJo	
software	(TreeStar).	
	
In	vitro	T	cell	differentiation	
Naïve	5C.C7	CD4	T	cells	were	cultured	with	irradiated	T	depleted	splenocytes	in	presence	
of	1µM	pigeon	cytochrome	c	peptide	for	3-4	days	with	various	combinations	of	antibodies	
and	cytokines:	IL-2,	IL-12	and	anti-IL-4	for	Th1	differentiation;	anti-IL-4,	anti-IFN-γ,	anti-
IL12,	IL-6,	TGFb,	IL-21	and	IL-23	for	Th17	differentiation.		Cells	were	then	rested	in	IL-2	
(Th1)	or	cytokine-free	medium	(Th17)	before	being	transferred	in	vivo.	
	
Immunohistochemistry	
Lung	lobes	were	perfused	and	immersed	in	5%	Formalin	before	staining	with	Hematoxylin	
and	Eosin	(American	Histolab,	Gaithersburg,	MD).		Images	were	acquired	using	a	Nikon	
Optiphot	microscope	equipped	with	Axiocam	HRc	Zeiss	camera.	
	
Statistical	analysis.	
Sample	sizes	were	determined	empirically.		No	animals	or	samples	were	excluded	from	the	
analysis,	and	no	randomization	or	blinding	was	used.		Differences	between	data	sets	of	
similar	variance	were	analyzed	by	unpaired	two-tailed	Student's	t-test.		A	p	value	>0.05	
was	considered	significant.	
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Figure	legend	
	
Figure	1	
Intranasal	immunization	with	LPS	induces	an	IL-17	response	
(a-b)	Cell	suspensions	from	Med	LN	and	lungs	of	recipients	of	5C.C7	cells	were	
restimulated	for	6h	with	PMA	and	ionomycin	6	days	after	intranasal	immunization	with	
LPS	+	PCC	and	stained	for	intracellular	cytokines	with	anti-IL-4,	anti-IL-13	(a)	or	anti-IFN-
γ,	and	anti-IL-17	(b).		Cells	were	gated	on	CD4+	CD45.1+/	CD45.2-.		(c)	Mean	(+/-	s.e.m.)	
percent	cytokine	producing	cells	in	Med	LN	and	lungs	of	control	animals	and	of	animals	
immunized	with	PCC	and	LPS.	****	p<0.001,	**p<0.02	comparing	PCC	+	LPS	immunization	
with	control	for	IL-17	production	by	Med	LN	and	lung	cells	(unpaired	Student	t-test)	[Data	
are	representative	of	two	(IL-4/	IL-13	and	FTY720)	or	>4	(IFN-γ/	IL-17)	separate	
experiments.]		(d)	Med	LN	and	PLN	cells	were	restimulated	with	PMA/	ionomycin	6	days	
after	immunization	in	the	hock.		FTY720	was	administered	12h	after	immunization.	5C.C7	
CD45.1	cells	were	analyzed	by	intracellular	staining	for	IFN-γ	and	IL-17.		(e)	Mean	(+/-	
s.e.m.)	percent	IFN-g-producing	cells	in	Med	LN	and	PLN	of	control	and	FTY-720	treated	
mice	immunized	with	PCC	and	LPS	in	the	hock.		[Data	are	representative	of	eight	(control)	
and	four	(FTY720)	mice	analyzed	in	two	separate	experiments]	****	p<0.001,	**p<0.02	
(unpaired	Student	t-test).		
	
Figure	2	
Intranasal	immunization	with	LPS	leads	to	Th17	differentiation	while	immunization	
with	poly(I:C)	leads	to	Th1	differentiation	
(a)	5C.C7	cells	were	transferred	to	wildtype	mice	and	immunized	with	LPS	+	PCC	or	
poly(I:C)	+	PCC.		(b)	Statistical	analysis	compares	frequency	of	IL-17-	and	IFN-g-producing	
cells	in	Med	LN	and	Lung	of	mice	immunized	with	LPS	or	poly(I:C)	as	adjuvant.		Data	are	
representative	of	>13	mice	from	4	different	experiments.		(mean	±	s.e.m.	****	p<0.001,	
unpaired	Student	t-test)	
	
Figure	3	
Roles	of	recipient	cells	in	the	cytokine	differentiation	
(a)	OT-II	CD4+	T	cells	were	transferred	into	wild	type,	TLR3-/-	and	IFNAR-/-	mice	that	were	
immunized	with	poly(I:C)	+	OVA.		Transferred	cells	were	gated	and	analyzed	as	in	figure	1	
for	production	of	IFN-g	and	IL-17.		(b)	Statistical	analysis	of	IL-17-	and	IFN-g-producing	
Med	LN	and	Lung	cells	from	IFNAR-/-	compared	to	control	mice	and	from	TLR3-/-	compared	
to	control	mice	was	performed	on	4	to	10	mice	from	>2	separate	experiments.		(mean	±	
s.e.m.	****	p<0.001,	unpaired	Student	t-test)	
(c)	OT-II	CD4+	T	cells	were	transferred	into	wild	type,	TRAM-/-	and	MyD88-/-	mice	that	were	
immunized	with	LPS	+	OVA.	Transferred	cells	were	analyzed	for	IFN-g	and	IL-17.		
(d)	Statistical	analysis	of	IL-17-	and	IFN-g-producing	Med	LN	and	Lung	cells	from	TRAM-/-	
mice	compared	to	control	mice	and	from	Myd88-/-	mice	compared	to	control	mice	was	
performed	on	4	to	10	mice	from	>2	separate	experiments.		(mean	±	s.e.m.	****	p<0.001,	***	
p<0.01,	unpaired	Student	t-test)	
(e)	Wild	type,	TRAM-/-	and	MyD88-/-	B6	mice	were	treated	with	LPS	or	poly(I:C).		Broncho	
alveolar	lavage	was	performed	18h	later,	and	fluid	analyzed	with	Cytokine	Bead	Array	for	
IL-6,	IL-10,	IFN-γ,	IL-12p70	and	IL-1b.		Data	are	derived	from	6	to	12	mice	from	4	separate	
experiments.		(Statistical	analysis	for	each	cytokine	compares	Myd88	+	LPS,	TRAM	+	LPS	
and	poly(I:C)	to	wt	+	LPS.	****	p<0.001,	***	p<0.01,	*	p<0.05)	
	
Figure	4	
IL-10	and	IL-12	control	IFN-γ	production	in	response	to	intranasal	immunization	
Wild	type	mice	received	106	5C.C7	T	cells	and	were	immunized	with	LPS	+	PCC	or	poly(I:C)	
+	PCC.		Transferred	5C.C7	T	cells	were	analyzed	for	IFN-γ	and	IL-17	production	6	days	after	
immunization.	
(a)	Mice	were	immunized	with	adjuvant	+	PCC	and	treated	with	exogenous	IL-10	12h	later.	
(c)	As	in	(a),	mice	were	treated	with	anti-IL-10	12h	before	immunization.		(e)	As	in	(a),	
mice	were	treated	with	IL-12,	or	anti-IL-12.		(b,	d,	f)	Data	are	representative	of	4	mice	in	2	
independent	experiments;	p	values	represent	comparisons	of	IL-17-	and	IFN-g-producing	
cells	from	control	mice	and	mice	treated	with	IL-10,	anti-IL-10,	IL-12	or	anti-IL-12	(mean	±	
s.e.m.	****	p<0.001,	**	p<0.02,	*	p<0.05	unpaired	Student	t-test).	
	Figure	5	
IL-1b	is	critical	for	IL-17	production	
(a)	Total	5C.C7	cell	numbers	in	Med	LN	7	days	after	intranasal	immunization	with	PCC	
+LPS,	PCC	+	LPS	+	IL-1b	or	PCC	+	LPS	+	IL-1Ra.		Statistical	analysis	was	performed	on	data	
from	8	mice	from	3	separate	experiments.	p	values	compare	LPS	+IL-1b	treated	mice	with	
LPS	only	treated	mice	(mean	±	s.e.m.	****	p<0.001,	unpaired	Student	t-test).		(b)	5C.C7	
transferred	cells	were	analyzed	for	IFN-g	and	IL-17	6	days	after	immunization	with	PCC	+	
LPS,	PCC	+	LPS	+	IL-1b	or	PCC	+	LPS	+	IL-1Ra.		(c)	Data	are	representative	of	>9	mice	
analyzed	in	3	separate	experiments;	p	values	represent	comparison	of	IL-17-producing	
cells	from	mice	treated	with	LPS+IL-1b	or	LPS	+	IL-1Ra	both	compared	to	LPS	only		(****	
p<0.001).		(d)	5C.C7	transferred	cells	were	analyzed	for	IFN-g	and	IL-17	6	days	after	
immunization	with	PCC	+	LPS	or	PCC	+	poly(I:C)	±	IL-1b.		(e)	Statistical	analysis	was	
performed	on	data	from	4	to	10	mice	in	3	separate	experiments.		p	values	compare	IL-17-	
or	IFN-g-producing	T	cells	from	LPS	+	IL-1b	and	LPS	only	treated	mice	or	of	poly(I:C)	+	IL-
1b	and	poly	(I:C)	only	treated	mice	(****	p<0.001,	**	p<0.02,	*	p<0.05)	
	
Figure	6	
IL-1b,	IL-10	and	IL-12	restore	cytokine	production	in	MyD88-/-		and	TRAM-/-		
recipients	
(a-b)	MyD88-/-	and	TRAM-/-	recipients	of	OT-II	CD4	T	cells	were	immunized	with	LPS	+	OVA	
and	treated	with	exogenous	IL-10,	IL-1b	or	IL-12.		Transferred	CD4	T	cells	were	analyzed	6	
days	later	for	IFN-γ	and	IL-17	production.		(c)	Statistical	analysis	was	performed	on	data	
from	4	mice	in	2	separate	experiments.		p	values	represent	comparisons	of	IL-17-	and	IFN-
γ-producing	cells	from	Myd88-/-	or	TRAM-/-mice	treated	with	LPS	+	IL-1b	or	with	LPS	+	IL-
10	to	similar	mice	treated	with	LPS	only	(mean	±	s.e.m.	***	p<0.01,	*	p<0.05,	unpaired	
Student	t-test)	
	
Figure	7	
IL-1b	induces	IL-17	production	by	endogenous	cells	during	influenza	infection	
(a-b)	B10.A	mice	were	infected	with	Tx91	influenza	virus	and	treated	3	days	later	with	
exogenous	IL-1b.		Med	LN	and	Lung	CD4	T	cells	were	analyzed	6	days	later	for	IFN-γ	and	
IL-17	production.		Statistical	analysis	was	performed	on	data	from	8	mice	in	3	separate	
experiments.		p	values	represent	a	comparison	of	IL-17-producing	cells	from	lungs	of	mice	
infected	with	Tx91	and	treated	with	IL-1b	to	that	of	mice	infected	with	Tx91	only	(mean	±	
s.e.m.	*	p<0.05,	unpaired	Student	t-test).	
	 	
Supplemental	Information	
	
Supplementary	Figure	1	
CD4	T	cells	undergo	rapid	activation	in	the	Med	LN	
Mice	that	received	106	5C.C7	CD45.1	CD4	T	cells	were	immunized	with	LPS	+	PCC.		Med	LN	
and	lung	cells	were	labelled	with	anti-CD45.1+/	CD45.2-	CD4+	and	analyzed	for	expression	
of:		(a)	CD69	and	CD62L	in	unimmunized	mice	and	at	6h	and	12h	after	immunization.		(b)	
CD44	and	CD45RB	in	unimmunized	mice	and	1.5,	2.5,	5	and	60	days	after	immunization.		
Data	are	representative	of	five	experiments.		(c)	CD4+	CD45.1+	transferred	cells	were	
followed	in	Med	LN,	PLN	and	Lungs	from	2h	to	90	days	after	immunization	(n	≥	3	mice	
analyzed	in	>2	experiments	per	data	point;	mean	±	s.e.m.).		
	
	 	
Supplementary	Figure	2	
Deletion	of	MyD88	or	TRAM	in	recipient	does	not	reduce	capacity	of	transferred	OT-
II	cells	to	produce	IFN-γ	upon	immunization	with	poly(I:C)	as	adjuvant	
OT-II	CD4+	T	cells	were	transferred	into	wild	type,	TRAM-/-	and	MyD88-/-	mice	that	were	
immunized	with	poly(I:C)	+	OVA.	Transferred	cells	were	analyzed	for	IFN-g	and	IL-17.	
	 	
Supplementary	Figure	3	
Th1	and	Th17-polarizing	cytokines	are	made	by	lung	macrophages	and	dendritic	
cells	
(a)	B/6	mice	were	immunized	with	LPS	or	poly(I:C)	for	48h.	Lungs	were	kept	in	vitro	in	the	
presence	of	monensin	for	6h,	and	stained	for	extracellular	markers	CD11c,	CD11b,	Siglec	F	
and	F4/80	and	intracellular	cytokines	IFNa,	pro-IL-1β,	IL-12p35,	IL-6	and	IL-23p19.			
(b)	Statistical	analysis	of	total	cell	numbers	was	performed	on	data	from	8	mice	per	group	
in	2	separate	experiments	(IFNa	p<0.0001,	pro	IL-1β	p=0.001,	IL-12p35	p<0.0001,	IL-6	
p=0.61,	IL-23p19	p<0.0001).	
	
	 	
Supplementary	Figure	4	
Exogenous	IL-1b	acts	on	responding	CD4	T	cells	
OT-II	CD4	T	cells	were	transferred	into	wild	type	or	IL-1R-/-	recipients,	immunized	and	
treated	with	exogenous	IL-1b.		Transferred	CD4	T	cells	were	analyzed	for	IFN-γ	and	IL-17	
production.	
	
	 	
Supplementary	Figure	5	
IL-1β-	dependent	enhanced	lung	infiltration	in	mice	infected	with	influenza	
Mice	were	infected	with	Tx91	influenza	virus	and	treated	3	days	later	with	exogenous	IL-
1b.		Lungs	were	harvested	and	stained	with	Haematoxylin	&	Eosin.		4X	pictures	show	
representative	staining	of	control	animals,	mice	infected	with	Tx91	influenza	virus	and	
infected	with	Tx91	virus	+	treated	with	IL-1β.		Bottom	right	picture	shows	20X	
magnification	of	Tx91	+	IL-1β	picture.	
	 	
Supplementary	Figure	6	
Exogenous	IL-1b	enhances	LCMV-induced	priming	for	IL-17	production	
B6	mice	were	infected	with	LCMV	by	intraperitoneal	injection.		3	days	later,	infected	
animals	were	treated	by	intranasal	administration	of	IL-1b.		Mice	were	analyzed	6	days	
later	for	cytokine	production.	
	
	 	
Abbreviations	
Med	LN:	Mediastinal	Lymph	Node	
PCC:	Pigeon	Cytochrome	c	
PLN:	Popliteal	Lymph	Node	
